{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:11:18Z","timestamp":1777896678845,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.acuroe.2026.501924","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:20:44Z","timestamp":1769271644000},"page":"501924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Confirmatory MRI and re-biopsy findings during active surveillance in patients with grade group 2 prostate cancer"],"prefix":"10.1016","volume":"50","author":[{"given":"F.","family":"Sanguedolce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Redondo R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Leni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Oderda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Al-Nader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Uleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Long-Depaquit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Baud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Benard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Windisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2026.501924_bib0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0010","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.acuroe.2026.501924_bib0015","first-page":"135","article-title":"Using active surveillance for Gleason 7 (3+4) prostate cancer: a narrative review","volume":"18","author":"Bernardino","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.acuroe.2026.501924_bib0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.juro.2017.03.123","article-title":"Intermediate-term outcomes for men with very low\/low and intermediate\/high risk prostate cancer managed by active surveillance","volume":"198","author":"Nyame","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","article-title":"Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study","volume":"78","author":"Stavrinides","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","article-title":"PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer","volume":"86","author":"Englman","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging - reporting and data system: 2015, version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0045","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0050","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","article-title":"Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations-a report of a European School of Oncology Task Force","volume":"71","author":"Moore","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0055","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/JU.0000000000001547","article-title":"Magnetic resonance imaging-targeted and systematic biopsy for detection of grade progression in patients on active surveillance for prostate cancer","volume":"205","author":"Yerram","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0060","first-page":"20","article-title":"Is confirmatory biopsy still necessary for active surveillance of men with grade group 1 prostate cancer in the era of multiparametric magnetic resonance imaging?","volume":"213","author":"Bhanji","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41391-023-00733-8","article-title":"Role of targeted biopsy, perilesional biopsy, random biopsy, and their combination in the detection of clinically significant prostate cancer by mpMRI\/transrectal ultrasonography fusion biopsy in confirmatory biopsy during active surveillance program","volume":"27","author":"Novara","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.acuroe.2026.501924_bib0070","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/pros.24556","article-title":"Upgrading on per protocol versus for cause surveillance prostate biopsies: an opportunity to decreasing the burden of active surveillance","volume":"83","author":"Wang","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.acuroe.2026.501924_bib0075","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JU.0000000000001339","article-title":"The clinical significance of multiple negative surveillance prostate biopsies for men on active surveillance-does cancer vanish or simply hide?","volume":"205","author":"Chu","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.juro.2018.07.051","article-title":"Predicting Gleason Group progression for men on prostate cancer active surveillance: role of a negative confirmatory magnetic resonance imaging-ultrasound fusion biopsy","volume":"201","author":"Bloom","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0085","doi-asserted-by":"crossref","first-page":"387.e9","DOI":"10.1016\/j.urolonc.2023.04.018","article-title":"Impact of a negative confirmatory biopsy on risk of disease progression among men on active surveillance for prostate cancer","volume":"41","author":"Salari","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0090","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1097\/JU.0000000000001701","article-title":"Association of negative followup biopsy and reclassification during active surveillance of prostate cancer: a systematic review and meta-analysis","volume":"205","author":"Rajwa","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0095","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0100","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.euo.2020.09.002","article-title":"Can the use of serial multiparametric magnetic resonance imaging during active surveillance of prostate cancer avoid the need for prostate biopsies?-A systematic diagnostic test accuracy review","volume":"4","author":"Hettiarachchi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.eururo.2020.06.030","article-title":"Multiparametric magnetic resonance imaging alone is insufficient to detect grade reclassification in active surveillance for prostate cancer","volume":"78","author":"Chu","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2026.501924_bib0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euros.2023.10.005","article-title":"Magnetic resonance imaging-guided active surveillance without annual rebiopsy in patients with grade group 1 or 2 prostate cancer: the prospective PROMM-AS study","volume":"59","author":"Valentin","year":"2023","journal-title":"Eur Urol Open Sci"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578626000272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578626000272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:34:02Z","timestamp":1777624442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578626000272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2173578626000272"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2026.501924","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Confirmatory MRI and re-biopsy findings during active surveillance in patients with grade group 2 prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2026.501924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2025.501924","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501924"}}